Year: 2023

Societal CDMO Announces Expansion of Controlled Substance Manufacturing Capabilities to Address Expanding Psychedelic Drug Development Market

Company Secures Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency, Expands on 25 Years of Manufacturing of Schedule...

Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023

HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation...

error: Content is protected !!